Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HSK29116 |
Synonyms | |
Therapy Description |
HSK29116 is a proteolysis-targeted chimera (PROTAC) that binds to Bruton's tyrosine kinase (BTK) and targets it for degradation, potentially leading to growth inhibition in BTK-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HSK29116 | HSK-29116|HSK 29116 | BTK inhibitor 37 | HSK29116 is a proteolysis-targeted chimera (PROTAC) that binds to Bruton's tyrosine kinase (BTK) and targets it for degradation, potentially leading to growth inhibition in BTK-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04861779 | Phase I | HSK29116 | A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies | Unknown status | AUS | 1 |